Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $26.31, down -4.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RARE shares have lost -10.84% over the last week, with a monthly amount drifted -28.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on June 06, 2024, and elevated its price target to $67. On April 22, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $77 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $72 on December 08, 2023. Evercore ISI upgraded its rating to Outperform for this stock on June 06, 2023, and upped its price target to $80. In a note dated April 26, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $114 on this stock.
Ultragenyx Pharmaceutical Inc [RARE] stock has fluctuated between $26.85 and $60.37 over the past year. Currently, Wall Street analysts expect the stock to reach $89.5 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $26.31 at the most recent close of the market. An investor can expect a potential return of 240.17% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 590.69M for the trailing twelve months, which represents a growth of 27.99%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.87%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.86 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.57 points at the first support level, and at 24.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.47, and for the 2nd resistance point, it is at 28.63.
Ratios To Look Out For
For context, Ultragenyx Pharmaceutical Inc’s Current Ratio is 2.40. As well, the Quick Ratio is 2.24, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 4.21, the price to book ratio is 17.10.
Transactions by insiders
Recent insider trading involved Sanders Corazon (Corsee) D., Director, that happened on Jun 20 ’25 when 2405.0 shares were sold. Director, CORAZON D. SANDERS completed a deal on Jun 20 ’25 to buy 2405.0 shares. Meanwhile, EVP and Chief Medical Officer Crombez Eric sold 520.0 shares on May 05 ’25.
